181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

D.Northfelt; C.E.Ooi; R.Gerwien; T.Hawthorne; A.Clarke; S.Jones; G.Rodriguez; P.Buhl-Jensen; D.Von Hoff; J.Grem

首页> 外文期刊>European Journal of Cancer Supplements >181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

【24h】

181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

机译：181后期A单独使用PXD101联合5-氟尿嘧啶治疗晚期实体瘤患者的Ib期Ib安全性和药效学研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
D.Northfelt; C.E.Ooi; R.Gerwien; T.Hawthorne; A.Clarke; S.Jones; G.Rodriguez; P.Buhl-Jensen; D.Von Hoff; J.Grem;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 357 POSTER A phase I safety, pharmacokinetic and pharmacodynamic study of intravenously administered PXD101 plus carboplatin or paclitaxel or both in patients with advanced solid tumors [J] . U.Lassen, M.S?rensen, J.S.De Bono, European Journal of Cancer Supplements . 2006,第12期

机译：357对晚期实体瘤患者静脉内施用PXD101联合卡铂或紫杉醇或两者同时进行的POSTER A期安全性，药代动力学和药效学研究
2. A phase ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: Cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors [J] . VermorkenJ.B., RotteyS., EhrnroothE., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第5期

机译：ib期开放性研究，用于评估阿法替尼与两种化疗方案（顺铂加紫杉醇和顺铂加5-氟尿嘧啶）持续口服治疗对晚期实体瘤患者的安全性
3. 218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors [J] . E.Calvo, G.Edelman, J.Baselga, European Journal of Cancer Supplements . 2008,第12期

机译：218海报A阶段I剂量递增研究XL147（一种新型PI3K抑制剂，对晚期实体瘤患者口服）的安全性，药代动力学和药效学
4. SAFETY EVALUATION OF COMBINATION DOXORUBICIN AND TOCERANIB PHOSPHATE (PALLADIA(R)) IN TUMOR BEARING DOGS: A PHASE I DOSE FINDING STUDY (VCS Award Winner) [C] . Pellin MA, Wouda RM, Robinson K, Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：肿瘤携带犬组合Doxorubicin和Toceranib磷酸盐（Palladia（R））的安全评估：I阶段查找研究（VCS奖获得者）
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety Pharmacokinetics Pharmacodynamics Analysis [O] . Marlies HG Langenberg, Petronella O Witteveen, Nienke AG Lankheet, 2010

机译：PTK 787 / ZK 222584和西妥昔单抗联合治疗晚期实体瘤患者的1期研究：安全性药代动力学药效学分析
7. Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis1 [O] . Langenberg, Marlies HG, Witteveen, Petronella O, Lankheet, Nienke AG, 2010

机译：PTK 787 / ZK 222584和西妥昔单抗联合治疗晚期实体瘤患者的1期研究：安全性，药代动力学，药效动力学分析1

181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅